Chicago Atlantic Real Estate Finance, Inc. (REFI) Earnings Call Transcript & Summary

May 7, 2026

NASDAQ US Real Estate Mortgage Real Estate Investment Trusts (REITs) earnings 29 min

Earnings Call Speaker Segments

Lisa Kampf

executive
#1

Thanks. Morning, everyone. Glad you could join us for the Chicago Atlantic Real Estate Finance Conference Call, where we'll walk through the company's results. Joining us today are Peter Sack, our Co-Chief Executive Officer; David Kite, President and Chief Operating Officer; and Phil Silverman, Chief Financial Officer. Earlier this morning, we put out our earnings press release with the results, and you can find it in the Investor Relations section of our website, together with our supplemental that was filed with the SEC. There's a live audio webcast available today. If you're listening to the replay, please note that what we say here reflects remarks as of today and won't be updated after this call. Throughout the call, some of our comments and statements may count as forward-looking statements under the meaning set by securities laws, including statements about how our portfolio may perform going forward, our pipeline of possible loans and other investments, upcoming dividends, and financing activities. Every forward-looking statement reflects Chicago Atlantic's judgment as of today's date, and risks and uncertainties could cause actual results to differ materially from what we currently expect. We encourage investors to review the various disclosures the company makes carefully, including the risks and other information in the company's SEC filings. We'll also go over certain non-GAAP measures, including but not limited to distributable earnings. You can find definitions of these non-GAAP measures, along with reconciliations to the most comparable GAAP measures, in our SEC filings. Now I'll hand things over to Peter Sack. Go ahead.

Peter Sack

executive
#2

Thanks, Lisa, and good morning to all. During this quarter, Chicago Atlantic delivered steady results even as worries persist in the private credit space, the Fed hit pause on its rate-cutting path after 3 straight reductions in Q4 of last year, and conflict in the Middle East stirred volatility; what we posted this quarter shows how sturdy and resilient our business model is. We rank among the top capital providers within the cannabis ecosystem. The know-how we've built in this sector gives us deep expertise, strong relationships, and the capacity to put capital back to work faster than a typical mortgage REIT could. Tight underwriting and demanding risk criteria, overseen by our team focused on cannabis underwriting, real estate, and analytics, keep the risk-reward equation acceptable. My optimism about the present landscape hasn't wavered. Our pipeline of cannabis deals stays robust, sitting right now at $482 million, and roughly $133 million of that total is secured by real estate collateral. With the medical rescheduling news that broke in late April, I would be remiss if I didn't call attention to the newest big federal move in cannabis policy. On April 23, the Department of Justice said it will move certain medical marijuana products from Schedule I to Schedule III; that marks the biggest federal policy shift in years, and arguably in the entire history of this industry. There are details still to sort out while we await a clearer framework and see how this policy interacts with each existing state law, and we anticipate these changes will hit every operator in a different way depending on how exposed they are to medical markets; still, after so many years of waiting, this represents an enormous move in the right direction. The main way we anticipate gaining an immediate advantage from this order is through wiping out the added tax load on cannabis businesses that stems from Section 280E, plus retroactive relief on older tax obligations, which ought to lift operator cash flows and shore up balance sheets, pushing valuation multiples higher and bettering the credit standing of the companies we lend to. This federal order mandates and establishes a fast-tracked mechanism for state-licensed medical cannabis operators to sign up with the DEA, essentially making state-licensed medical cannabis legal at the federal level. One more plus would be reduced obstacles to listing on U.S. exchanges, something we've long pushed for. An administrative hearing is set for June 29 to July 15; that proceeding opens a route toward rescheduling cannabis on a wider basis, potentially including adult-use products. We'll stay cautious in expecting a favorable result and avoid getting ahead of ourselves. In our view, Chicago Atlantic is positioned well to gain from the initial order. And as I've said previously, none of these changes are required for our strategy to succeed. We've stayed conservative and underwrite each investment as if no regulatory-driven credit gains will materialize. As we approach the June 29 hearing, we've started modeling various possible results coming out of the rule-making process, though at this point we're still taking a wait-and-see approach. On the whole, REFI turned in steady, reliable financial performance during the first quarter of 2026, even with a macro backdrop that's been volatile. Because our business model is differentiated — we lend to operators and property owners within the cannabis sector — we're able to function in a specialized niche where competition is limited, securing advantageous terms and generating attractive yields; this year is shaping up as a period of major change for cannabis, after the federal government moved medical marijuana from Schedule I to Schedule III, plus the chance of wider policy changes affecting cannabis later in the year. Seeing our business model validated, along with the possible effects of regulatory orders making their way through to REFI, gives us encouragement. I'm eager to share updates on how we're doing over the remainder of what should be a thrilling year. David is going to walk through the portfolio in more depth now. David?

David Kite

executive
#3

Thanks, Peter. At the close of March 31, the principal balance on our loan book came to roughly $414 million, spread over 25 companies in the portfolio, and the weighted average yield to maturity stood at 15.8%, versus 16.3% in Q4 of 2025. New originations for the quarter amounted to about $54 million in principal fundings — $16.2 million went to new borrowers and $37.8 million to borrowers we already had. Those were partly offset by roughly $52 million in repayments, which broke down into $3.3 million of scheduled amortization and $48.2 million from borrowers prepaying their loans in full or in part. On March 31, 2026, about 10.7% of the portfolio carried a risk rating of 4 or above, up from 4.8% on December 31, 2025. That shift in risk ratings was mainly due to loan #36, which was downgraded from a 3 to a 4, and it drove an increase of roughly $3.8 million in CECL reserves. During our prior call, I noted that we'd made substantial headway on loan #9 in the previous quarter by advancing funds to the borrower so they could pursue accretive acquisitions. By December 31, 2025, that loan had been brought current. And now, as of March 31, we're happy to report that after 3 straight months of on-time payments and evidence of lasting operational improvement, we've returned the loan to accrual status — which we believe positions it to keep meeting its debt service obligations going forward. This really showcases how we bring together the workout and operational know-how of our team and the wider Chicago Atlantic platform, applying creativity and hands-on deal management to achieve a successful turnaround. On March 31, 2026, roughly 4.8% of the portfolio sat on nonaccrual status, down from approximately 11.1% on December 31, 2025, with the main driver being loan #9's return to accrual. Also as of March 31, 2026, fixed rate loans made up 35.2% of the portfolio while floating rate loans accounted for 64.8%; of those floating rate loans, 71.9% are tied to the prime rate and 28.1% to SOFR. With prime currently at 6.75%, every one of our prime-based loans sits at its floor. All told, only about 4% of our loan principal across the entire portfolio has any exposure to additional rate cuts. A key point: none of our floating rate loans carry interest rate caps, and that — together with our rate floor protections — gives us a structural edge in how we build the portfolio, one that stacks up well against most other mortgage REITs. Total leverage was 38% of book equity on March 31, compared with 32% on December 31. On March 31, we had $67.1 million drawn on our senior secured revolving credit facility and $49.4 million drawn on our unsecured term loan. As of today, about $59 million remains available on the senior credit facility, and total liquidity, net of estimated liabilities, is roughly $54 million. I'll hand things over now to Phil.

Phil Silverman

executive
#4

Thanks, David. Net interest income came in at $13.1 million for the first quarter, which was down $1.2 million, or 8%, from $14.2 million in the fourth quarter of 2025. That decline mostly came from the fourth quarter's collection of past due unaccrued interest tied to loan #9, which totaled $1.7 million and was recognized last quarter. Total interest expense, including noncash amortization of financing costs, was roughly $2 million for the first quarter of 2026, up from $1.8 million in the fourth quarter. Weighted average borrowings under our revolving loan rose to $48 million, versus $33.6 million in the fourth quarter. As of March 31, 2026, our CECL reserve on loans held for investment stood at approximately $8.7 million. Measured relative to size, our reserve for expected credit losses equals 2.1% of the outstanding principal on our loans held for investment. That reserve grew by about $3.8 million from the fourth quarter, largely because of LTV increases tied to specific loans — mainly loan #4, 34, and loan #36; on a weighted average basis, our portfolio kept strong real estate coverage of 1.2x. Distributable earnings per weighted average share, basic and fully diluted, were approximately $0.47 and $0.46 for the first quarter. In April, we paid the fourth quarter dividend of $0.47 per common share that our Board declared. Since inception, the company has paid out $8.94 per common share in dividends — a yield on cost of roughly 11.8% measured against our IPO price. Book value per common share outstanding was $14.39 as of March 31, 2026, and roughly 21.5 million common shares were outstanding on a fully diluted basis as of that date. From April 1, 2026, through today, the company advanced new growth loan principal of about $15.8 million — $13.1 million to a new borrower and $2.7 million to existing borrowers on delayed draw under existing credit facilities. The company also received $14.3 million in total loan repayments — $1.8 million of scheduled amortization and $12.5 million in early prepayments, including full repayment of loans #6 and #30; based on our basic distributable earnings per share, we expect to keep a dividend payout ratio of 90% to 100% for the 2026 tax year. Should our taxable income call for additional distributions beyond the regular quarterly dividend to satisfy our taxable income requirements, we expect to satisfy that with a special dividend in the fourth quarter. Operator, we're now ready to take questions.

Pablo Zuanic

analyst
#5

Thanks, Peter, for those remarks about the regulatory side and, naturally, the encouraging updates we've gotten lately. I'd like to begin with loan #36. Clearly, 4 and 34 are Arizona loans, and we're aware that market is difficult for growers. You noted that 4 and 34 sit in accruals or fall within the reserve. As for 36, that one's an Illinois loan, correct? It's also a bigger loan, $27 million. Any additional detail you could share on it would be useful. Arizona, I get it; Illinois, obviously, we've watched Forefront and other businesses run into problems there. But if you could offer more color specifically on loan #36, that would help, please. Particularly given it was issued in December 2024, which isn't very long ago, I believe.

Peter Sack

executive
#6

Thank you. The Illinois market is going through consolidation on the retail side, and I'd say it's seeing growing competition in cultivation. This particular one has solid real estate coverage and operates as a vertically integrated business. And the — I believe the reserving activity mirrors our routine assessment of how portfolio companies are performing and the risk involved. Our conversations with the borrower have been quite constructive. And we anticipate that this can be — this company's results can be enhanced and worked out in a constructive, collaborative way; and I'm hopeful that over the coming months, we'll look back on this reserving activity as conservative. But either way, this fits within our continuing effort to demonstrate reserving activity that captures a conservative read on portfolio performance.

Pablo Zuanic

analyst
#7

Staying on that same subject, Peter, could you provide an update regarding loans 4 and 34?

Peter Sack

executive
#8

Those two keep — keep moving forward. My sense is that it's too soon to offer detailed updates, though the relationships remain constructive.

Pablo Zuanic

analyst
#9

And in that same vein, regarding loan #9, going back into accruals, as you mentioned, you were deeply engaged with them in a cooperative manner. I'm simply attempting to grasp what potential exists for loans in the portfolio that might be equitized or where you could manage to attract new purchasers for those loans. How should we view that as a future opportunity for the book?

Peter Sack

executive
#10

I believe it's crucial to set loan #9 apart from other reserving activities across the portfolio, and loan #9 involved a foreclosure process — specifically a judicial foreclosure process. That requires a considerably longer period to resolve compared to when difficult circumstances at portfolio companies can be settled productively and through cooperation. I would say that markets for assets facing difficulties have gotten much better over the past 12 months, as rescheduling expectations shifted from speculative to more certain to, regarding medical operators, completed. This constitutes an environment that is both favorable and constructive for putting capital to work and for discovering solutions inside the book, whether that means locating new equity investors, carrying out operational change, or steering toward an exit. This setting is superior for both deployment and reorganization and problem solving than anything we've truly observed over the last 3 years.

Pablo Zuanic

analyst
#11

Right. Now regarding those repayments that weren't scheduled, I appreciate the table. In today's press release, you indicated roughly $48 million of unscheduled repayment during the first quarter; and I believe Phil referenced an additional $15 million already in the second quarter. Does that fall outside the usual pattern? I'm simply attempting to grasp what's causing those early repayments, or whether it's just a normal part of the course.

Peter Sack

executive
#12

These are part of the course, and we labeled them unscheduled, but unscheduled doesn't necessarily mean a surprise; and these were loans that many — a few of them were approaching their maturity date.

Pablo Zuanic

analyst
#13

Okay, a few more, and I apologize if there's anybody else waiting in the queue. So, in the 10-Q, loan #45 up in Canada — I'm not sure whether this marks your first loan outside the U.S., so could you speak to that? And then, stepping back, what about international opportunities, Europe, and especially Canada?

Peter Sack

executive
#14

It isn't our first — perhaps it's the first instance of REFI executing a loan outside the U.S., but as a platform, Chicago Atlantic has executed loans outside the U.S. before, and in Canada too. What we're seeing, I think, is that in the Canadian market there's been stabilization in certain cases, along with rationalization, meaning unprofitable operators are exiting; that's created room and breathing space for operators that are profitable and executing well to rise to the top, get recognized, demonstrate strong results, and open up chances for lenders to deploy capital at very attractive risk-adjusted returns. In the past, I think we simply hadn't seen that opportunity set emerge so meaningfully, so specifically, or so clearly. But this is something we observe across many markets that are oversaturated — they go through a rationalization period, and once that rationalization happens, pockets of opportunity appear.

Pablo Zuanic

analyst
#15

Just one more. I realize we've discussed...

Chris Muller

analyst
#16

I'd like to get some points cleared up regarding Schedule III that you might or might not have information on right now. To start, I suppose, what share of your portfolio is medical? And how, I guess, does that get figured out? Is it figured out at the license level — my understanding is certain states issue adult-use licenses? Or does it get figured out based on whether the end user is medical or rec?

Peter Sack

executive
#17

The majority of our borrowers who run as adult use also run as medical operators. Every one of them then breaks down their revenue into medical versus adult use, though in many cases those medical and adult-use sales can come from the very same dispensary. We haven't made public what portion is medical or versus adult use. My hope is that by 2026 this won't matter, that the administrative hearings set for June and July move forward, that adult use gets rescheduled too. Then the industry won't need to go through this exercise of figuring out what's medical and what's adult use — it could just run each business seamlessly. But we'll see. I believe that if adult-use measures and progress on adult-use rescheduling stall or slow, then you'll see a great deal of effort among our borrowers to break down medical versus adult-use operations so they can allocate costs in the best way between their medical and adult-use operations to get the most tax efficiency. And I believe you'll also see state regulators possibly tweaking the definitions inside their adult-use program to move more of their operations toward what they can label and designate a medical program; but my hope is that kind of maneuvering won't be needed since the administration has carried out its pathway to reschedule the whole supply chain.

Chris Muller

analyst
#18

Understood, that's useful. And I believe I noticed California pursuing a similar path, and I agree with your take on it. With any luck, that matters and the full Schedule III is wrapped up in June, though we'll have to wait and see how it goes; then, regarding the CECL reserve increase this quarter, and maybe I overlooked this in the prepared remarks you all gave, but did that increase fall under specific or general reserves? And what's your thinking on how Schedule III will affect CECL reserves?

Peter Sack

executive
#19

That reserve movement combined both specific and general. The — I want to point out that this reserve movement captures the market, discount rates, valuations, and loan to values as of 3/31, and it doesn't capture what came afterward with rescheduling market activity and discount rates. I'd say in general, the rescheduling is a — in my view, the rescheduling benefits credit for every one of our borrowers, including those without meaningful medical revenues.

Chris Muller

analyst
#20

Is it reasonable to think there will be some CECL releases at points during 2026 while those 280E matters get resolved at the companies?

Peter Sack

executive
#21

That could absolutely happen; what it would represent is a mirror, not exactly of rescheduling itself, but rather of the underlying assumptions — of how the market feels, loan to values, and cash flow calculations — feeding into the assumptions behind our CECL reserve policies and behaviors.

Chris Muller

analyst
#22

It's good to hear that at last there's something encouraging happening in this sector.

Aaron Grey

analyst
#23

So, first off, clearly everyone's hoping the full plant gets rescheduled for late summer or fall after the hearings wrap up; though it's possible that in the near term, or if the full plant reschedule happens, things take somewhat longer. Under that scenario, might you become somewhat more aggressive in medical-only states where, as you know, 280E has been removed? Or does that alter any of the possible near-term landscape opportunities?

Peter Sack

executive
#24

I believe it does permit us — what's the — it permits us to be — to account in our underwriting for how medical revenues and adult-use revenues are taxed differently. And I believe it pushes us to — we'll need to — should adult-use sales not move forward, then I think that leads to, I think, distinct lenses for medical versus adult use simply because it creates differing cash flow dynamics for the operators. And that's the core foundation that I think every underwriter in this space is going to have to adjust. Once more, I wish it weren't necessary. But should cash flow fundamentals be mirrored in this, that will also be mirrored in our underwriting and deployment.

Aaron Grey

analyst
#25

That's useful context. A number of folks across the industry mention the possible effects of the hemp ban taking effect in November, and how that might reach the broader legal cannabis sector. I'm curious about your perspective on it, and on your borrowers — the possibility of that actually happening and giving a lift to your borrowers' fundamentals, plus how you see it.

Peter Sack

executive
#26

I've definitely picked up anecdotal feedback that revenue has risen because of the hemp ban, especially in states where smoke shops are more common and where those kinds of black market hemp CBD and cannabis-adjacent products show up more. Finding a direct connection in the data, I think, has been tough, though there are certainly anecdotal and correlative ties linking the hemp ban with regulated cannabis sales.

Aaron Grey

analyst
#27

All right, that's my final question. Regarding liquidity and pipeline, can you give any sense of when certain pipeline items might materialize, given the liquidity you still have on hand?

Peter Sack

executive
#28

I'd say — our pipeline generally renews itself on a 3 to 6 month cycle. During that window, we get the chance to assess whether the deals sitting in the pipeline are ones we want to close or ones that ultimately aren't worth closing; but it's — I believe forecasting what that deployment will look like within that timeframe is tough, whether things go well or poorly. And here — I should mention that this quarter, at the request of investors, we put out a breakdown separating Canada — separating real estate backed from non-real estate loans in our portfolio, aiming to give our investors a clearer picture of which portion of our pipeline is more directly suited to Chicago Atlantic real estate financing.

Operator

operator
#29

Since no one else has anything to ask, that brings the Q&A portion to a close. In addition, today's conference call has ended; we appreciate your participation in the presentation, and you're free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Chicago Atlantic Real Estate Finance, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Chicago Atlantic Real Estate Finance, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Chicago Atlantic Real Estate Finance, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.